Skip to main
DERM
DERM logo

DERM Stock Forecast & Price Target

DERM Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Journey Medical Corp has demonstrated significant market traction, with payer access for its products increasing from approximately 30% of commercial lives in May to around 65% by July, affecting over 100 million lives. Additionally, the uptick in prescriber adoption from about 660 in the first quarter to over 1,800 in the second quarter signifies a robust growth trajectory. Furthermore, established brand value, particularly for key products like Accutane, enhances consumer retention and aids in maintaining market share.

Bears say

Journey Medical Corp exhibits a concerning trend in its prescription volume, as evidenced by the significant decline in Accutane prescriptions from 93,000 in Q1 2024 to approximately 66,000 in Q1 2025, which may negatively impact overall revenue. The company faces notable risks, including heightened competitive pressure from both branded and generic treatments, slower than anticipated uptake of its product Emrosi, and potential reimbursement pushback by payers. Additionally, ongoing regulatory and clinical risks, along with potential challenges in managing cash burn and effectively scaling its sales force, further contribute to a bearish outlook for the stock.

DERM has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Journey Medical Corp and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Journey Medical Corp (DERM) Forecast

Analysts have given DERM a Strong Buy based on their latest research and market trends.

According to 3 analysts, DERM has a Strong Buy consensus rating as of Dec 9, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $12.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $12.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Journey Medical Corp (DERM)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.